The burgeoning interest in state-regulated psychedelic therapies, driven by the potential benefits for treating various medical conditions, stands at a critical juncture with federal law and FDA regulations. The evolving landscape, marked by initiatives in states like Oregon and Colorado, reflects a need for careful navigation to avoid conflicts and ensure compliance.
Legal on paper, restricted in practice. Inside Germany’s cannabis system, where cultivation is allowed but…
The idea may sound strange: a tobacco plant producing compounds like psilocybin or DMT. Sounds…
The term “addiction” gets thrown around quite freely in everyday language—this is nothing new. Who…
Three days before the Trump administration moved medical marijuana to Schedule III, a new YouGov…
On April 23, 2026, the Trump administration officially moved FDA-approved marijuana products and marijuana products…
Here we are in 2026, and a conflict that was supposed to wrap up in…